Last reviewed · How we verify
Granulocyte Colony Stimulating Factor
Granulocyte Colony Stimulating Factor is a Small molecule drug developed by Emory University. It is currently FDA-approved. Also known as: G-CSF, Filgrastim.
Granulocyte Colony Stimulating Factor (G-CSF) is a type of somatic cell supplemental therapy used to stimulate the production of white blood cells. It has been studied in clinical trials for various conditions, including Spontaneous Bacterial Peritonitis, Multiple Myeloma, Non-Hodgkin's Lymphoma, Hodgkin's Disease, and Myelogenous Leukemia.
At a glance
| Generic name | Granulocyte Colony Stimulating Factor |
|---|---|
| Also known as | G-CSF, Filgrastim |
| Sponsor | Emory University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma (PHASE2)
- Improving White Blood Cell Collection From Healthy Donors (PHASE4)
- A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) (PHASE2, PHASE3)
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
- Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer (PHASE2, PHASE3)
- A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant (PHASE1)
- Pilot Study of Reduced-Intensity Hematopoietic Stem Cell Transplant of DOCK8 Deficiency (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Granulocyte Colony Stimulating Factor CI brief — competitive landscape report
- Granulocyte Colony Stimulating Factor updates RSS · CI watch RSS
- Emory University portfolio CI
Frequently asked questions about Granulocyte Colony Stimulating Factor
What is Granulocyte Colony Stimulating Factor?
Who makes Granulocyte Colony Stimulating Factor?
Is Granulocyte Colony Stimulating Factor also known as anything else?
What development phase is Granulocyte Colony Stimulating Factor in?
Related
- Manufacturer: Emory University — full pipeline
- Also known as: G-CSF, Filgrastim
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing